CITIUS ONCOLOGY, INC.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTOR$0.56+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
| Exhibit Number · Description of Document · Registrant’s Form · Dated · Exhibit Number · Filed Herewith | ||||
|---|---|---|---|---|
| 2.1* | Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 10/24/2023 | 2.1 |
| 3.1.1 | Certificate of Incorporation of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.1 |
| 3.1.2 | Certificate of Amendment to the Certificate of Incorporation of Citius Oncology, Inc., filed with the Secretary of State of the State of Delaware on April 7, 2025. | 10-Q | 08/12/2025 | 3.2 |
| 3.2 | Bylaws of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.2 |
| 4.1 | Specimen Common Stock Certificate of Citius Oncology, Inc. | S-4 | 07/11/2024 | 4.5 |
| 4.2 | Warrant Agency Agreement, dated as of July 17, 2025, by and between Citius Oncology, Inc. and Equiniti Trust Company, LLC. | 8-K | 07/18/2025 | 4.1 |
| 4.3 | Form of Common Warrant. | 8-K | 07/18/2025 | 4.2 |
| 4.4 | Form of Placement Agent Warrant. | 8-K | 07/18/2025 | 4.3 |
| 4.5 | Form of Common Warrant. | 8-K | 09/10/2025 | 4.1 |
| 4.6 | Form of Placement Agent Warrant. | 8-K | 09/10/2025 | 4.2 |
| 4.7 | Form of Common Warrant. | 8-K | 12/10/2025 | 4.1 |
| 4.8 | Form of Pre-funded Warrant. | 8-K | 12/10/2025 | 4.2 |
| 4.9 | Form of Placement Agent Warrant. | 8-K | 12/10/2025 | 4.3 |
| 4.10 | Description of Common Stock. | 10-K | 12/27/2024 | 4.2 |
| 10.1 | Amended and Restated Registration Rights Agreement, dated as of August 12, 2024 by and between Citius Oncology, Inc. and the signatories thereto. | 8-K | 08/16/2024 | 10.1 |
| 10.2 | Amended and Restated Shared Services Agreement, dated as of August 12, 2024, by and among Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.2 |
| 10.3† | 2023 Omnibus Stock Incentive Plan. | 10-K | 12/27/2024 | 10.3 |
| 10.4.1† | 2024 Omnibus Stock Incentive Plan. | 8-K | 08/5/2024 | 10.5 |
| 10.4.2† | Amendment to the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan. | 8-K | 09/19/2025 | 10.1 |
| 10.5* | Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s Laboratories S.A. and Citius Pharmaceuticals, Inc. | S-4 | 11/13/2023 | 10.15 |
| 10.6.1* | Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.16 |
| 10.6.2* | Amendment No. 1 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.17 |
| 10.6.3* | Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.18 |
| 10.7 | Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 08/16/2024 | 10.8 |
| 10.8 | Promissory Note, dated July 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 07/18/2023 | 10.1 |
| 10.9 | Promissory Note, dated October 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 10/18/2023 | 10.1 | |
| 10.10.1 | Promissory Note, dated August 16, 2024, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.9 | |
| 10.10.2 | Amendment to Promissory Note, dated September 10, 2025, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 09/10/2025 | 10.3 | |
| 10.10.3 | Second Amendment to Promissory Note, dated December 10, 2025, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 12/10/2025 | 10.5 | |
| 10.11 | Placement Agency Agreement, dated as of July 16, 2025, by and between Citius Oncology, Inc. and Maxim Group LLC. | 8-K | 07/18/2025 | 10.1 | |
| 10.12 | Securities Purchase Agreement, dated as of July 16, 2025, by and between Citius Oncology, Inc. and the purchasers named therein. | 8-K | 07/18/2025 | 10.2 | |
| 10.13 | Placement Agency Agreement, dated as of September 9, 2025, by and between Citius Oncology, Inc. and Maxim Group LLC. | 8-K | 09/10/2025 | 10.1 | |
| 10.14 | Form of Securities Purchase Agreement, dated as of September 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 09/10/2025 | 10.2 | |
| 10.15 | Form of Registered Direct Securities Purchase Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.1 | |
| 10.16 | Form of PIPE Securities Purchase Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.2 | |
| 10.17 | Form of Registration Rights Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.3 | |
| 10.18 | Form of Warrant Amendment Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.4 | |
| 19.1 | Insider Trading Policy. | 10-K | 12/27/2024 | 19.1 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | -- | -- | -- | X |
| 31.1 | Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 31.2 | Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 32.1 | Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. | -- | -- | -- | X |
| 97.1 | Policy Relating to Recovery of Erroneously Awarded Compensation | 10-K | 04/16/2024 | 97.1 | |
| EX-101.INS | INLINE XBRL INSTANCE DOCUMENT | -- | -- | -- | X |
| EX-101.SCH | INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | -- | -- | -- | X |
| EX-101.CAL | INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | -- | -- | -- | X |
| EX-101.DEF | INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | -- | -- | -- | X |
| EX-101.LAB | INLINE XBRL TAXONOMY EXTENSION LABELS LINKBASE | -- | -- | -- | X |
| EX-101.PRE | INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | -- | -- | -- | X |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL) | -- | -- | -- | X |
| * | Portions of this exhibit have been omitted pursuant to Item 601(b)10 of Regulation S-K or certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2) or 601(a)(5), as applicable. Citius Oncology agrees to furnish supplementally an unredacted copy such exhibit, including any omitted exhibits and schedules, to the SEC upon its request. |
|---|
| † | Indicates management contract or compensatory plan. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.